Global Market Access Complexity Grows As The World’s Biggest Pharma Markets React To Reforms And Emerging Markets Turn Their Attention To New Pricing Regulation

March 6, 2014

Decision Resources Group’s Country Experts Evaluate Global Commercial Environment in New Market Access Tracker Analysis

BURLINGTON, Mass., March 6, 2014 /PRNewswire/ — Decision Resources Group finds that landmark healthcare legislation in developed markets across the globe, combined with evolving regulatory trends in emerging markets, has created a more complex global market access environment. Even as the world’s biggest pharma market–the United States–is in the throes of Healthcare Reform, Japan is ramping up its processes for health technology assessment (HTA). At the same time, emerging markets throughout Asia and Latin America are actively crafting biosimilar regulations and scrutinizing drug reimbursement policies to attain greater value for money. Market-specific data and insights are the only way for businesses concerned with global market access to navigate such complexity.


Key Facts:

    --  The proposed publication of discounted prices in Germany may have a
        profound effect on drug prices around the world through its impact on
        international reference pricing.
    --  Compulsory licensing is increasing in India, and may gain traction in
    --  Japan's evolving approach to price premiums for the most innovative
        drugs has driven a new focus on HTA.
    --  U.S. Healthcare Reform and cost-containment efforts in Germany are
        examples of quickly evolving landscapes where the relative importance of
        different analytics and datasets is rapidly changing.
    --  Global market opportunity--in scope or approach--can change in a matter
        of months, like accepted business practices resulting from the bribery
        scandal in China or the new pricing regulations in India or Turkey.
    --  Market entry strategy includes ever-changing pricing, reimbursement and
        market access hurdles.  Accurate insight to the country-specific context
        is critical.  Key questions include:
        --  Who are the important healthcare decision makers?
        --  How important is health technology assessment?
        --  What are the characteristics of regulatory affairs and intellectual
            property protection?
        --  What procedures govern price setting and admission to reimbursement?
        --  What are the key demographic trends in each country?
        --  How developed is the healthcare infrastructure?
        --  Will patients have access to innovative brands through insurance


    --  Mike Latwis, Senior Director at Decision Resources Group, said: "Global
        trade agreements, regional economic alliances and the harmonization of
        regulatory policies create a constant, ever-changing flow of market
        access opportunities and challenges.   For example, policies vary
        greatly within the Asia Pacific region, so companies doing business
        there should consider the relative value of conducting clinical trials
        in Taiwan, developing biosimilars in South Korea or securing local
        manufacturing in Indonesia. The ability to quickly and easily assess
        accurate cross-country comparisons of key market access drivers and
        statistics is crucial to grasp the underlying dynamics in each market
        and speed any associated decision-making process."
    --  Roy Moore, Senior Director at Decision Resources Group, adds: "In the
        United States, market access has been broadly affected by the Affordable
        Care Act (ACA) and the increasing prominence of accountable care
        organizations, clinical pathways and drug acquisition strategies.
        Specific therapies and the way brands market to them continue to be
        profoundly impacted. Pharma companies are creating and executing
        strategy amid this rapidly changing environment in the United States
        while managing other country-specific change internationally. The
        critical question for forward-looking drug firms is whether they are
        nimble enough to leverage these evolving, nation-specific changes to
        maximize market share across the globe."

Additional Resources:

    --  Find clarity in the face of complexity with Decision Resources Group's
        NEW Asia Pacific Healthcare Market Statistics Infographic. To download,


About Market Access Tracker

Market Access Tracker offers expert commercial insights and deep global coverage. An online market visualizer interface allows users to view market statistics and answer business questions on an interactive, map-based platform. In-depth, intuitive country profiles on 30 countries across four world regions, effortless access to expert country analysts, succinct Commercialization Outlooks and easily internalized Pricing and Reimbursement Flowcharts offer clarity in the face of global market access complexity. Find out more about the Market Access Tracker here and here.

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Chris Comfort

Decision Resources Group



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus